BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating

Reuters

Jan 27, 2025

** JonesTrading starts coverage on drug developer Sagimet Biosciences SGMT.O with "buy" rating, sets PT at $42

** PT represents 900% upside to stock's last close

** Brokerage says co's experimental drug, denifanstat, is "overlooked potential" in treating metabolic dysfunction-associated steatohepatitis (MASH)

** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage

** JonesTrading notes denifanstat has " best-in-disease potential for fibrosis improvement as GLP-1 combo" with "well-derisked lead asset" in expanding market

** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034

** SGMT fell 15.6% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2506153377"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506153377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2506153377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-27 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506153377","market":"us","top_or_hot":-1,"title":"BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating</title></head><body><p>** JonesTrading starts coverage on drug developer Sagimet Biosciences <span>SGMT.O</span> with \"buy\" rating, sets PT at $42</p><p>** PT represents 900% upside to stock's last close</p><p>** Brokerage says co's experimental drug, denifanstat, is \"overlooked potential\" in treating metabolic dysfunction-associated steatohepatitis (MASH)</p><p>** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage</p><p>** JonesTrading notes denifanstat has \" best-in-disease potential for fibrosis improvement as GLP-1 combo\" with \"well-derisked lead asset\" in expanding market</p><p>** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034</p><p>** SGMT fell 15.6% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-27 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating</title></head><body><p>** JonesTrading starts coverage on drug developer Sagimet Biosciences <span>SGMT.O</span> with \"buy\" rating, sets PT at $42</p><p>** PT represents 900% upside to stock's last close</p><p>** Brokerage says co's experimental drug, denifanstat, is \"overlooked potential\" in treating metabolic dysfunction-associated steatohepatitis (MASH)</p><p>** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage</p><p>** JonesTrading notes denifanstat has \" best-in-disease potential for fibrosis improvement as GLP-1 combo\" with \"well-derisked lead asset\" in expanding market</p><p>** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034</p><p>** SGMT fell 15.6% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMT","symbol_name":"Sagimet Biosciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL3N3ON0XG:1","article_id":"2506153377","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506153377","pubTimestamp":1737986158,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating** JonesTrading starts coverage on drug developer Sagimet Biosciences SGMT.O with \"buy\" rating, sets PT at $42** PT represents 900% upside to stock's last close** Brokerage says co's experimental drug, denifanstat, is \"overlooked potential\" in treating metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** JonesTrading notes denifanstat has \" best-in-disease potential for fibrosis improvement as GLP-1 combo\" with \"well-derisked lead asset\" in expanding market** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034** SGMT fell 15.6% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SGMT":"Sagimet Biosciences Inc."},"translate_title":"BUZZ-JonesTrading开始对药物开发商Sagimet给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":0.9},"content_text":"BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating** JonesTrading starts coverage on drug developer Sagimet Biosciences SGMT.O with \"buy\" rating, sets PT at $42** PT represents 900% upside to stock's last close** Brokerage says co's experimental drug, denifanstat, is \"overlooked potential\" in treating metabolic dysfunction-associated steatohepatitis (MASH)** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** JonesTrading notes denifanstat has \" best-in-disease potential for fibrosis improvement as GLP-1 combo\" with \"well-derisked lead asset\" in expanding market** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034** SGMT fell 15.6% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}